Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
September 18, 2018 10:55 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on...
Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares
September 13, 2018 19:06 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on...
Foamix Announces Proposed Follow-on Offering of Ordinary Shares
September 12, 2018 16:31 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on...
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
September 11, 2018 17:00 ET
|
Foamix, Ltd.
FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Tomorrow at 8:00 a.m. EDT ...
Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 08, 2018 16:01 ET
|
Foamix, Ltd.
REHOVOT, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8
August 01, 2018 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
CORRECTING and REPLACING -- Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
June 27, 2018 09:04 ET
|
Foamix, Ltd.
Top-line results expected early Q4 2018 In a release issued under the same headline earlier today by Foamix (NASDAQ:FOMX), please note that in the second paragraph of the release, the top-line data...
Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
June 27, 2018 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics Summit
June 14, 2018 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., June 14, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 17:04 ET
|
Foamix, Ltd.
REHOVOT, Israel, May 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and...